Compare AstraZeneca plc (AZN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Under Armour Inc Class A — how do they compare? AstraZeneca plc trades at $158.8 (market cap $248.14B), while Under Armour Inc Class A trades at $5.17 (market cap $2.26B). The key difference: AstraZeneca plc is far larger — about 109.8× Under Armour Inc Class A's market cap, and AstraZeneca plc pays a 2.01% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| AZN | UA | |
|---|---|---|
Market Cap | $248.14B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $7.88 |
52-Week Low | $147.06 | $3.96 |
Enterprise Value | $275.41B | $3.24B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Under Armour (UA) trades at $5.20, down 8.37% amid weak quarterly results and lowered revenue guidance. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability (net margin -9.99%). Recent news highlights softer consumer demand in key markets, though the company maintains its profitability outlook.
The outlook remains challenging with significant execution risks and competitive pressures. While analyst sentiment is mixed (38.81% Buy, 49.25% Hold), the stock's deep value metrics (P/S 0.45) may attract contrarian investors if operational improvements materialize. Key risks include sustained revenue declines and negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
